Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2023-01-17 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1916 characters) and contains the header "RNS Number : 0189N". It announces a 'Price Monitoring Extension' for a security, which is a specific, short-form operational update related to trading on the London Stock Exchange. It explicitly mentions RNS (the news service of the London Stock Exchange) and its role as a Primary Information Provider. This type of brief, operational regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2023-01-17 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1933 characters) and contains the header 'RNS Number : 9988M' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, short-form regulatory market announcement related to trading halts or volatility controls. This type of brief, immediate market notification that doesn't fit into the specific financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing (RNS). It is not an announcement of a report (RPA) but a direct regulatory update.
2023-01-17 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1916 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing the 'RNS Number' and stating that the information is provided by RNS, the news service of the London Stock Exchange, approved by the Financial Conduct Authority (FCA). This is a general regulatory announcement that does not fit the specific categories like ER, IR, 10-K, or DIV. Since it is a standard, brief regulatory notification distributed via the RNS system, the most appropriate classification is the general Regulatory Filings category.
2023-01-17 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1933 characters) and contains the header 'RNS Number : 9745M'. It discusses a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, IR, or 10-K. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or DLST), the most appropriate classification is the general Regulatory Filings category.
2023-01-17 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1916 characters) and announces a 'Price Monitoring Extension' related to an auction call period on the London Stock Exchange. It explicitly mentions 'RNS Number' and is distributed by 'RNS, the news service of the London Stock Exchange,' which is approved by the FCA. This is a general regulatory announcement that does not fit the specific categories like ER, IR, 10-K, or DIRS. Given its nature as a routine, non-specific regulatory update distributed via the RNS system, the most appropriate classification is the general Regulatory Filings category.
2023-01-17 English
Successful Completion of Fourth Dose Escalation
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 9050M' and contains language typical of a regulatory news service announcement, including references to 'Avacta Group plc' and the date '17 January 2023'. The content announces clinical trial progress ('Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study') and includes boilerplate language about 'inside information' and being published via a 'Regulatory Information Service ('RIS')'. This structure strongly indicates a general regulatory news release that does not fit the specific definitions of 10-K, ER, IR, or DIV. Since it is a general announcement disseminated through the RNS system and doesn't fit a more specific category like DIRS, MANG, or CAP, the most appropriate fallback category is Regulatory Filings (RNS). The document length (9831 chars) is substantial, but the primary identifier is the RNS header and closing statements.
2023-01-17 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.